Clinical significance of 18F-FDG PET/CT in colorectal carcinoma;18F-FDG PET/CT klinikai alkalmazása colorectalis carcinomában

Orvosi Hetilap

Volumn 154, Issue 37, 2013, Pages 1447-1453

  Németh, Zsuzsanna ^a   Boér, Katalin ^a   Kásler, Miklós ^a   Borbély, Katalin ^a  

^a Onkológiai Osztály ^*  (Hungary)

Author keywords

18F FDG PET CT; colorectal cancer; metabolic response; PERCIST; RECIST; SUV

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

COLORECTAL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; HYBRID; POSITRON EMISSION TOMOGRAPHY; REVIEW; SOLID TUMOR; TREATMENT RESPONSE; CANCER STAGING; CARCINOMA; COLORECTAL TUMOR; HUMAN; LIVER TUMOR; METABOLISM; METASTASIS; METHODOLOGY; PATHOLOGY; PREDICTIVE VALUE; TREATMENT OUTCOME; TUMOR RECURRENCE; COLORECTAL NEOPLASMS; DIAGNOSTIC USE; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PROCEDURES; SECONDARY;

CARCINOMA; COLORECTAL NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84884265885     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2013.29700     Document Type: Review

References (41)

1. Borbély, K. The place of positron-emission tomography in contemporary patient care. [A pozitronemissziós tomográfia helye a korszer betegvezetésben.] Orv. Hetil., 1999, 140, 171-178. [Hungarian]
2. Townsend, D. W. Combined PET/CT: the historical perspective. Semin. Ultrasound CT MR, 2008, 29, 232-235.
3. Borbély, K., Szilágyi, I., Kásler, M. Statement of the Fourth National Multidisciplinary Consensus Conference on PET/CT. [IV. PET/CT Multidiszciplináris Nemzeti Konszenzus Konferencia Állásfoglalása.] Magyar Onkológia, 2011, 55, 117-127. [Hungarian]
4. Li, Z., Conti, P. S. Radiopharmaceutical chemistry for positron emission tomography. Adv. Drug Deliv. Rev., 2010, 62, 1031-1051.
5. World Health Organization Global cancer rates could increase by 50% to 15 million by 2020. http://www.who.int/mediacentre/news/releases/2003/pr27/en/ ">http://www.who.int/mediacentre/news/releases/2003/pr27/en/
6. Mitry, E., Guiu, B., Cosconea, S., et al. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut, 2010, 59, 1383-1388.
7. Manfredi, S., Lepage, C., Hatem, C., et al. Epidemiology and management of liver metastases from colorectal cancer. Ann. Surg., 2006, 244, 254-259.
8. Mantke, R., Schmidt, U., Wolff, S., et al. Incidence of synchronous liver metastases in patients with colorectal cancer in relationship to clinico-pathologic characteristics. Results of a German prospective multicentre observational study. Eur. J. Surg. Oncol., 2012, 38, 259-265.
9. Van Cutsem, E., Nordlinger, B., Cervantes, A. and On behalf of the ESMO Guidelines Working Group Advanced colorectal cancer: ESMO Clinical practice guidelines for treatment. Ann. Oncol., 2010, 21 (Suppl. 5), v93-v97.
10. Facey, K., Bradbury, I., Laking, G., et al. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess (Winchester, England), 2007, 11, iii-iv, xi-267.
11. Tsunoda, Y., Ito, M., Fujii, H., et al. Preoperative diagnosis of lymph node metastases of colorectal cancer by 18FDG-PET-CT. Jpn. J. Clin. Oncol., 2008, 38, 347-353.
12. Tateishi, U., Maeda, T., Morimoto, T., et al. Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer. Eur. J. Nucl. Med. Mol. Imaging, 2007, 34, 1627-1634.
13. Bipat, S., Glas, A. S., Slors, F. J. M., et al. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT and MR imaging-a meta-analysis. Radiology, 2004, 232, 773-783.
14. Abdel-Nabi, H., Doerr, R. J., Lamonica, D. M., et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology, 1998, 206, 755-760.
15. Kosugi, C., Saito, N., Murakami, K., et al. Positron emission tomography for preoperative staging in patients with locally advanced or metastatic colorectal adenocarcinoma in lymph node metastasis. Hepato-gastroenterology, 2008, 55, 398-402.
16. Adam, R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann. Oncol., 2003, 14 (Suppl. 2), ii13-ii16.
17. Adam, R., Wicherts, D. A., de Haas, R. J., et al. Patients with initially unresectable colorectal liver metastases: Is there a possibility of cure J. Clin. Oncol., 2009, 27, 1829-1835.
18. Adam, R., Aloia, T., Lévi, F., et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J. Clin. Oncol., 2007, 25, 4593-4602.
19. Cunningham, D., Humblet, Y., Siena, S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med., 2004, 351, 337-345.
20. Hurwitz, H., Fehrenbacher, L., Novotny, W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2004, 350, 2335-2342.
21. Madoff, D. C., Hicks, M. E., Vauthey, J. N., et al. Transhepatic portal vein embolization: anatomy, indications, and technical considerations. RadioGraphics, 2002, 22, 1063-1076.
22. Lam, V. W. T., Laurence, J. M., Johnston, E., et al. A systematic review of two-stage hepatectomy in patients with initially unresectable colorectal liver metastases. HPB (Oxford), 2013, 15, 483-491.
23. Rappeport, E. D., Loft, A., Berthelsen, A. K., et al. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol., 2007, 48, 369-378.
24. Adie, S., Yip, C., Chu, F., et al. Resection of liver metastases from colorectal cancer: does preoperative chemotherapy affect the accuracy of PET in preoperative planning ANZ J. Surg., 2009, 79, 358-361.
25. Sahani, D. V., Kalva, S. P., Fischman, A. J., et al. Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. Am. J. Roentgenol., 2005, 185, 239-246.
26. Bipat, S., Leeuwen, M. S., Comans, E. F. I., et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta-analysis. Radiology, 2005, 237, 123-131.
27. Fletcher, J. W., Djulbegovic, B., Soares, H. P., et al. Recommendations on the use of 18F-FDG PET in oncology. J. Nucl. Med., 2008, 49, 480-508.
28. Adam, R., De Gramont, A., Figueras, J., et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist, 2012, 17, 1225-1239.
29. Byström, P., Berglund, A., Garske, U., et al. Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D- glucose positron emission tomography in patients with advanced colorectal cancer. Ann. Oncol., 2009, 20, 1057-1061.
30. Anzidei, M., Napoli, A., Zaccagna, F., et al. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: Evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging. J. Comput. Assist. Tomogr., 2011, 35, 690-696.
31. Valk, P. E., Abella-Columna, E., Haseman, M. K., et al. Whole-body PET imaging with [18F] fluorodeoxyglucose in management of recurrent colorectal cancer. Arch. Surg., 1999, 134, 503-511.
32. McCall, J. L., Black, R. B., Rich, C. A., et al. The value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Dis. Colon Rectum, 1994, 37, 875-881.
33. Park, K. C., Schwimmer, J., Gambhir, S. S., et al. Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann. Surg., 2002, 235, 309-310.
34. Even-Sapir, E., Parag, Y., Lerman, H., et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology, 2004, 232, 815-822.
35. Buijsen, J., van den Bogaard, J., van der Weide, H., et al. FDG-PET-CT reduces the interobserver variability in rectal tumor delineation. Radiother. Oncol., 2012, 102, 371-376.
36. Borbély, K. Functional imaging in oncology. In: Kasler, M. (ed.): Fundamentals of oncology. [Funkcionális képalkotás az onkológiában. In: Kasler, M. (szerk.): Az onkológia alapjai.] Medicina Könyvkiadó, Budapest, 2011, 229-256. [Hungarian]
37. Cantwell, C. P., Setty, B. N., Holalkere, N., et al. Liver lesion detection and characterization in patients with colorectal cancer: a comparison of low radiation dose non-enhanced PET/CT, contrast-enhanced PET/CT, and liver MRI. J. Comput. Assist. Tomogr., 2008, 32, 738-744.
38. Eschmann, S. M., Friedel, G., Paulsen, F., et al. Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancer. Lung Cancer, 2007, 55, 165-171.
39. Young, H., Baum, R., Cremerius, U., et al. Measurement of clinical and subclinical tumour response using [18F]-uorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur. J. Cancer, 1999, 35, 1773-1782.
40. Wahl, R. L., Jacene, H., Kasamon, Y., et al. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med., 2009, 50 (Suppl. 1), 122S-150S.
41. Kim, J. H., Czernin, J., Allen-Auerbach, M. S., et al. Comparison between 18F-FDG-PET in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J. Nucl. Med., 2005, 46, 587-595.